New Company Joins With RPR To Develop Intrabody Technology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.

An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content